This was the stock's third consecutive day of gains.

Explore the latest news on 23andMe as a U.S. judge approves its sale amid privacy concerns and consumer issues.

Regeneron Pharmaceuticals has announced it will acquire 23andMe, the once high-flying consumer DNA testing company, for $256 million through a bankruptcy auction.

Regeneron Pharmaceuticals is purchasing genetics and biotechnology company 23andMe and has vowed to protect customer data while continuing genome testing services.

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.